410 related articles for article (PubMed ID: 18494804)
21. The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes.
Howlett H; Porte F; Allavoine T; Kuhn T; Nicholson G
Curr Med Res Opin; 2003; 19(3):218-25. PubMed ID: 12803736
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
Penfornis A; Borot S; Raccah D
Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
[TBL] [Abstract][Full Text] [Related]
23. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
24. Management of type 2 diabetes mellitus with special reference to metformin therapy.
Campbell IW
Diabete Metab; 1991 May; 17(1 Pt 2):191-6. PubMed ID: 1936475
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.
Raskin P; McGill J; Saad MF; Cappleman JM; Kaye W; Khutoryansky N; Hale PM;
Diabet Med; 2004 Apr; 21(4):329-35. PubMed ID: 15049934
[TBL] [Abstract][Full Text] [Related]
26. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
27. Insulin in type 2 diabetes: a useful alternative despite limited assessment based on surrogate endpoints.
Prescrire Int; 2005 Oct; 14(79):187-93. PubMed ID: 16285076
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
Rudovich NN; Leyck Dieken MG; Rochlitz H; Pfeiffer AF
Exp Clin Endocrinol Diabetes; 2004 Jul; 112(7):395-400. PubMed ID: 15239026
[TBL] [Abstract][Full Text] [Related]
29. [Could oral antidiabetic agents be useful in the management of different types of diabetes and syndromes of insulin resistance in children and adolescents?].
Otto-Buczkowska E; Nowowiejska B; Jarosz-Chobot P; Stańczyk J
Przegl Lek; 2009; 66(7):388-93. PubMed ID: 20043582
[TBL] [Abstract][Full Text] [Related]
30. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
[TBL] [Abstract][Full Text] [Related]
31. Treatment of type 2 diabetes with combined therapy: what are the pros and cons?
Massi-Benedetti M; Orsini-Federici M
Diabetes Care; 2008 Feb; 31 Suppl 2():S131-5. PubMed ID: 18227473
[TBL] [Abstract][Full Text] [Related]
32. Metformin revisited: re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents.
Goodarzi MO; Bryer-Ash M
Diabetes Obes Metab; 2005 Nov; 7(6):654-65. PubMed ID: 16219009
[TBL] [Abstract][Full Text] [Related]
33. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
Wenying Y; Benroubi M; Borzi V; Gumprecht J; Kawamori R; Shaban J; Shah S; Shestakova M; Ligthelm R; Valensi P;
Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
[TBL] [Abstract][Full Text] [Related]
34. [Triple oral therapy in type 2 diabetes].
Scheen AJ
Rev Med Suisse; 2005 Aug; 1(30):1942, 1944-6, 1948. PubMed ID: 16200937
[TBL] [Abstract][Full Text] [Related]
35. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
Halimi S
Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
[TBL] [Abstract][Full Text] [Related]
36. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study.
De Mattia G; Laurenti O; Moretti A
Acta Diabetol; 2009 Mar; 46(1):67-73. PubMed ID: 19030772
[TBL] [Abstract][Full Text] [Related]
37. Updated review: improved glycemic control with repaglinide-metformin in fixed combination for patients with type 2 diabetes.
Richard JW; Raskin P
Clin Med Insights Endocrinol Diabetes; 2011; 4():29-37. PubMed ID: 22879792
[TBL] [Abstract][Full Text] [Related]
38. A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes.
Moses R
Expert Opin Pharmacother; 2000 Dec; 1(7):1455-67. PubMed ID: 11249478
[TBL] [Abstract][Full Text] [Related]
39. Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy.
Wang W; Bu R; Su Q; Liu J; Ning G
Expert Opin Pharmacother; 2011 Dec; 12(18):2791-9. PubMed ID: 21780853
[TBL] [Abstract][Full Text] [Related]
40. Pathophysiology and treatment of patients with type 2 diabetes exhibiting failure to oral drugs.
Efendic S; Alvarsson M; Brismar K; Wagner H
Acta Physiol (Oxf); 2008 Jan; 192(1):117-25. PubMed ID: 18171434
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
